NCT00034359View on ClinicalTrials.gov

Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

January 31, 2003

Study Completion Date

January 31, 2003

Conditions
Hepatitis B, Chronic
Interventions
DRUG

ACH-126,443

DRUG

Lamivudine

DRUG

Placebo

Trial Locations (3)

Unknown

Clinical Trial Site, Sofia

Clinical Trial Site, Belgrade

Clinical Trial Site, Novi Sad

Sponsors
All Listed Sponsors
collaborator

Achillion, a wholly owned subsidiary of Alexion

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY